CA2822921C - Gemcabene and derivatives thereof for treating or preventing pancreatitis - Google Patents

Gemcabene and derivatives thereof for treating or preventing pancreatitis Download PDF

Info

Publication number
CA2822921C
CA2822921C CA2822921A CA2822921A CA2822921C CA 2822921 C CA2822921 C CA 2822921C CA 2822921 A CA2822921 A CA 2822921A CA 2822921 A CA2822921 A CA 2822921A CA 2822921 C CA2822921 C CA 2822921C
Authority
CA
Canada
Prior art keywords
compound
subject
gemcabene
pancreatitis
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2822921A
Other languages
English (en)
French (fr)
Other versions
CA2822921A1 (en
Inventor
Charles L. Bisgaier
Original Assignee
Gemphire Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gemphire Therapeutics LLC filed Critical Gemphire Therapeutics LLC
Publication of CA2822921A1 publication Critical patent/CA2822921A1/en
Application granted granted Critical
Publication of CA2822921C publication Critical patent/CA2822921C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2822921A 2010-12-27 2011-12-22 Gemcabene and derivatives thereof for treating or preventing pancreatitis Active CA2822921C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061427236P 2010-12-27 2010-12-27
US61/427,236 2010-12-27
PCT/US2011/066736 WO2012092103A1 (en) 2010-12-27 2011-12-22 Gemcabene and derivatives for treating pancreatitis

Publications (2)

Publication Number Publication Date
CA2822921A1 CA2822921A1 (en) 2012-07-05
CA2822921C true CA2822921C (en) 2018-07-17

Family

ID=45498140

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2822921A Active CA2822921C (en) 2010-12-27 2011-12-22 Gemcabene and derivatives thereof for treating or preventing pancreatitis

Country Status (14)

Country Link
US (1) US8846761B2 (enExample)
EP (2) EP2658536B1 (enExample)
JP (3) JP2014509305A (enExample)
CN (2) CN107648210A (enExample)
AU (1) AU2011352449B2 (enExample)
CA (1) CA2822921C (enExample)
DK (1) DK2658536T3 (enExample)
ES (1) ES2608177T3 (enExample)
HK (1) HK1250484A1 (enExample)
HU (1) HUE031004T2 (enExample)
MX (1) MX337593B (enExample)
PL (1) PL2658536T3 (enExample)
PT (1) PT2658536T (enExample)
WO (1) WO2012092103A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3218349A2 (en) 2014-11-14 2017-09-20 Gemphire Therapeutics Inc. Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers
MX2018005096A (es) * 2015-11-06 2018-08-15 Gemphire Therapeutics Inc Combinaciones de gemcabeno para el tratamiento de enfermedad cardiovascular.
EP3612171A4 (en) 2017-04-18 2020-10-21 Gemphire Therapeutics Inc. GEMCABENE, PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, COMPOSITIONS THEREOF AND PROCEDURES FOR THE USE OF THE SAME

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011852A1 (fr) * 1988-06-06 1989-12-14 Showa Denko Kabushiki Kaisha Agent de traitement de la pancreatite ou similaire
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
US20020103252A1 (en) 1997-12-12 2002-08-01 Bisgaier Charles Larry Statin-carboxyalkylether combinations
US6861555B2 (en) 2000-01-25 2005-03-01 Warner-Lambert Company Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
US20030105154A1 (en) * 2001-10-24 2003-06-05 Bisgaier Charles Larry Statin-carboxyalkylether combinations
US6459003B1 (en) 1999-04-01 2002-10-01 Esperion Therapeutics, Inc. Ether compounds
MXPA03003021A (es) * 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
US6645170B2 (en) 2001-03-05 2003-11-11 Bioject Medical Technologies, Inc. Simplified disposable needle-free injection apparatus and method
US20040229954A1 (en) * 2003-05-16 2004-11-18 Macdougall Diane Elaine Selective manipulation of triglyceride, HDL and LDL parameters with 6-(5-carboxy-5-methyl-hexyloxy)-2,2-dimethylhexanoic acid monocalcium salt
US7345190B2 (en) 2003-11-12 2008-03-18 Ssv Therapeutics, Inc. Carnitine conjugates as dual prodrugs and uses thereof

Also Published As

Publication number Publication date
US8846761B2 (en) 2014-09-30
JP6207560B2 (ja) 2017-10-04
PT2658536T (pt) 2016-12-22
DK2658536T3 (en) 2017-01-09
HK1250484A1 (zh) 2018-12-21
CN103442707A (zh) 2013-12-11
US20120165411A1 (en) 2012-06-28
HUE031004T2 (en) 2017-06-28
AU2011352449A1 (en) 2013-07-11
EP3170495B1 (en) 2023-04-26
PL2658536T3 (pl) 2017-04-28
JP2016028075A (ja) 2016-02-25
MX337593B (es) 2016-03-11
EP3170495A1 (en) 2017-05-24
CA2822921A1 (en) 2012-07-05
EP2658536B1 (en) 2016-10-19
WO2012092103A1 (en) 2012-07-05
JP2018027953A (ja) 2018-02-22
CN107648210A (zh) 2018-02-02
MX2013007310A (es) 2013-10-25
ES2608177T3 (es) 2017-04-06
JP2014509305A (ja) 2014-04-17
AU2011352449B2 (en) 2015-06-18
EP2658536A1 (en) 2013-11-06

Similar Documents

Publication Publication Date Title
JP6295205B2 (ja) 心血管疾患のリスクを低減する方法
EP3370713A1 (en) Treatment of mixed dyslipidemia
EP4376832B1 (en) Obicetrapib for use in treating of cardiovascular disease (cvd) in his hyporesponders
AU2011352449B2 (en) Gemcabene and derivatives for treating pancreatitis
AU2015202580B2 (en) Gemcabene and derivatives for treating pancreatitis
HK1238159A1 (en) Gemcaben for treating pancreatitis
EA020237B1 (ru) Способ снижения смертности от сердечно-сосудистых событий
HK1192147A (en) Gemcabene and derivatives for treating pancreatitis
WO2004096276A9 (ja) 糖取り込み能増強剤
RU2779839C2 (ru) Композиции твердых растворов и их применение при хроническом воспалении
WO2008015763A1 (fr) Formulation médicamenteuse contenant un médicament fibrate et procédé pour la produire
ROBINSON Pharmacologic treatment of dyslipidemia and cardiovascular disease
HK40007806A (en) Methods of reducing risk of cardiovascular disease
Ganda Lipid management in the metabolic syndrome
HK1098953A1 (zh) 高脂血症治疗药剂
HK1098953B (en) Hyperlipemia therapeutic agent

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20150529

H11 Ip right ceased following rejected request for revival

Free format text: ST27 STATUS EVENT CODE: T-6-6-H10-H11-H101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TIME LIMIT FOR REVERSAL EXPIRED

Effective date: 20250625

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20251106